The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
From Its 2026 Market Size, What Value Is The Biologic & Biosimilar RA Drugs Market Projected To Reach By 2030?
The market size for biologic & biosimilar ra drugs has experienced substantial growth in recent years. It is anticipated to increase from $14.57 billion in 2025 to $15.55 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.8%. The expansion observed in prior periods is attributable to the rising prevalence of rheumatoid arthritis, limited availability of treatment options, growing investment in biologics research, increasing healthcare expenditure, and the patent expiry of key biologics.
The market size for biologic & biosimilar ra drugs is anticipated to experience robust expansion over the coming years. This market is projected to reach $20.53 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.2%. Factors contributing to this growth during the forecast period include the increasing uptake of biosimilars, innovations in drug delivery technology, augmented manufacturing capabilities, supportive regulations for biologics, and heightened understanding of precision medicine. Key developments expected in the forecast timeframe encompass individualized biologic treatments, accelerated adoption of biosimilars, sophisticated drug delivery mechanisms, unified regulatory frameworks for biologics, and efforts to optimize costs in ra treatments.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9255&type=smp
Which Important Drivers Are Guiding The Biologic & Biosimilar RA Drugs Market Growth?
The expanding expenditure on healthcare is anticipated to drive the advancement of the biologic and biosimilar RA drug market. This spending represents the overall financial commitment from individuals, governments, and various organizations towards medical products and services, covering costs for preventing, treating, and managing health issues. Biologic and biosimilar RA drugs play a crucial role in optimizing the management of rheumatoid arthritis, offering a balance between effectiveness and affordability for the specialized and frequently costly treatments that are part of healthcare expenditures. For example, data from November 2023, provided by CIHI, a health information institute based in Canada, projects that Canada’s total health spending will hit $344 billion in 2023, equating to $8,740 per person. This signifies a 2.8% rise in 2023, contrasting with a modest 1.5% increase observed in 2022. Consequently, the rise in healthcare spending is a key factor propelling the biologic and biosimilar RA drug market.
What Are The Different Segment Types In The Biologic & Biosimilar RA Drugs Market Segment Breakdown?
The biologic & biosimilar ra drugs market covered in this report is segmented –
1) By Source: Microbial, Mammalian, Other Sources
2) By Manufacturing: Outsourced, In-House
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Microbial: Bacterial Sources, Fungal Sources, Yeast Sources
2) By Mammalian: Chinese Hamster Ovary (CHO) Cells, Human Embryonic Kidney (HEK) Cells, Other Mammalian Cell Lines
3) By Other Sources: Plant-Based Sources, Insect-Based Sources, Synthetic Biology Approaches
Which Trends Are Shaping The Biologic & Biosimilar RA Drugs Market?
Leading companies in the biologic & biosimilar RA drugs market are prioritizing the creation of innovative solutions, such as dual-concentration biosimilar formulations, to address the increasing demand for cost-effective, readily available, and user-friendly alternatives to expensive biologics. These dual-concentration biosimilar options provide both high- and low-strength formulations that accurately mimic branded biologics, thus facilitating continuous treatment and enhancing patient convenience compared to traditional single-concentration biologics. As an illustration, in July 2023, Organon, a US-based healthcare company, and Samsung Bioepis, a South Korea-based biopharmaceutical company, introduced HADLIMA, a biosimilar of Humira (adalimumab), in the US. Offered in both high and low concentrations, HADLIMA aims to improve access and affordability for individuals with autoimmune diseases. The biosimilar is priced at an 85% discount to Humira, thereby contributing to broader patient access. HADLIMA incorporates an autoinjector, endorsed by the Arthritis Foundation, and a patient support initiative, HADLIMA For You, which offers educational resources and co-pay assistance. It is prescribed for various ailments, including rheumatoid arthritis and Crohn’s disease. HADLIMA is provided in both citrate-free high concentration (100 mg/mL) and citrate-containing low concentration (50 mg/mL), ensuring seamless continuity of care for patients.
Who Are The Well-Known Companies In The Biologic & Biosimilar RA Drugs Market?
Major companies operating in the biologic & biosimilar ra drugs market are Samsung BioLogics Co. Ltd., Amgen Inc., AbbVie Inc., Johnson & Johnson Services Inc., Pfizer Inc., Merck & Co. Inc., Eli Lilly and Company, Novartis AG, Bayer AG, F. Hoffmann-La Roche Ltd., AstraZeneca PLC, Teva Pharmaceutical Industries Ltd., Fresenius SE & Co. KGaA, Stada Arzneimittel AG, Boehringer Ingelheim Pharmaceuticals Inc., Gedeon Richter Plc., La Roche Ltd., Regeneron Pharmaceuticals Inc., Bristol-Myers Squibb Company, Dr. Reddy’s Laboratories Ltd., Biogen Inc., Genentech Inc., GlaxoSmithKline plc, Mylan N.V., Sandoz International GmbH, Amneal Pharmaceuticals LLC, Apotex Inc., Biocon Ltd., Coherus BioSciences Inc.
Get The Full Biologic & Biosimilar RA Drugs Market Report:
Which Region Leads The Biologic & Biosimilar RA Drugs Market In Overall Market Size?
North America was the largest region in the biologic & biosimilar RA drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the biologic & biosimilar RA drugs market report during the forecast period. The regions covered in the biologic & biosimilar ra drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Biologic & Biosimilar RA Drugs Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Biologic & Biosimilar RA Drugs Market 2026, By The Business Research Company
Biologic And Biosimilar Ra Drugs Market Report 2026
Rheumatoid Arthritis Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/rheumatoid-arthritis-drugs-global-market-report
Rheumatoid Arthritis Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/rheumatoid-arthritis-drugs-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model